CohBar, Inc. announced an update on the timing for the release of the data for its Phase 1a/1b clinical study of CB4211 for the potential treatment of nonalcoholic steatohepatitis and obesity. The process of data entry and final validation by the company’s clinical research organization, which must be concluded prior to database lock, is ongoing. Once the database is locked, external biostatisticians will have access to the unblinded data from the study, enabling them to perform the data analysis and generate the final output. Only after this process is complete will the data be provided to the company. The company currently expects to release topline data prior to Labor Day 2021. CB4211 is a first-in-class mitochondria based therapeutic (MBT) that has demonstrated significant therapeutic potential in preclinical models of nonalcoholic steatohepatitis (NASH) and obesity. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring mitochondrial derived peptide (MDP), which was discovered by CohBar founder Dr. Pinchas Cohen and his academic collaborators and has been shown to play a significant role in the regulation of metabolism. NASH has been estimated to affect as many as 30 million adults in the U.S., and there is currently no approved treatment for the disease.